Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERMIXON 160 mg versus placebo in LUTS due to BPH
2014-000222-38Phase 4Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Permixon 160 mg twice daily with Placebo (2 arms). Started Mar 2014; status: completed.
02
Drugs
saw palmetto fruit extract
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2014-000222-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000222-38.